Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Chemical Biology - The Future? | Main | Avandia Goes Down: A Research Rant »

September 23, 2010

Delightful, But It Apparently Works

Email This Entry

Posted by Derek

And I now present today's winner of the Ugliest Molecule To Actually Show In Vivo Efficacy. Here, just in time for lunch, is Torin-1, a selective mTOR inhibitor. Yowza.
torin.jpg

Comments (30) + TrackBacks (0) | Category: Chemical News


COMMENTS

1. ronathan richardson on September 23, 2010 12:13 PM writes...

Finally. They've been writing papers that use that thing to prove a key point for 2 years now, with no actual structural data. Doesn't look reactive, at least. Aggregation-prone, possibly. What a strange core.

Permalink to Comment

2. d on September 23, 2010 12:14 PM writes...

It will be renamed Candlewaxin

Permalink to Comment

3. ronathan richardson on September 23, 2010 12:19 PM writes...

On second look it appears to be highly similar to NVP-BEZ235, which is less ugly and has incredible efficacy in tumor models.

Permalink to Comment

4. student on September 23, 2010 12:26 PM writes...

I have little knowledge of med chem. Can someone explain how this can be a drug since it looks like brick dust and is extremely unlikely to be water soluble?

Permalink to Comment

5. Grayscale Rainbow on September 23, 2010 12:30 PM writes...

Oh, come on Derek, fess up. You know somewhere in your career you've made a compound or two (or more) with a MW~600 and cLogP ~6, which weren't even active in vitro, much less in vivo. Most of us have but we're too ashamed to admit it, unless of course one of them is in the clinic.

Permalink to Comment

6. milkshake on September 23, 2010 12:35 PM writes...

I think this one still has some solubility left because there are no free NH in the molecule.

For another horrific example of an oral drug design, see itraconazole and posaconazole

Permalink to Comment

7. EngelGW on September 23, 2010 12:42 PM writes...

@student I don't know its solubility but the conformation of such a compound in 3D is far away as it looks like in 2D. Due to several ortho substituants, some crystal packing effects are avoided.

Permalink to Comment

8. HelicalZz on September 23, 2010 12:45 PM writes...

Some quibbles,

First the title 'Discovery of ..' makes me think natural product. But it is clear from the abstract (if not the structure), that this was 'Developed' from a scaffold, not 'Discovered'. I find use of discover in these situations to be something of an insult to the chemists.

A good definition of ugly is 'cellular IC50 = 2 nM, efficacious dose 20 mg/kg'.

To the authors credit, they propose the compound as a 'useful probe' of the mTOR pathway, not as a drug.

Zz

Permalink to Comment

9. Otis on September 23, 2010 12:48 PM writes...

I'm a nerd that I know what this could be useful for, but I don't think it'll pass through the blood/brain barrier well...

Permalink to Comment

10. Otis on September 23, 2010 1:07 PM writes...

Isn't rapamycin an Alzheimer's drug? By the same pathway, I guess it's cancer too.

Permalink to Comment

11. Bryan on September 23, 2010 1:16 PM writes...

I would bet that it has substantial off-target actions at other classes of molecular targets (GPCRs, hERG, MDR-1 and so on).


To their credit they did counter-screen 400 kinases!

Permalink to Comment

12. bfs on September 23, 2010 1:22 PM writes...

@14 - Isn't rapamycin an Alzheimer's drug?

Immunosuppressant.

Permalink to Comment

13. partial agonist on September 23, 2010 1:37 PM writes...

Holy Lipinski, Batman...

My chemdraw saws MW 608 and cLogP a whopping 6.2...

Permalink to Comment

14. ZZ on September 23, 2010 1:39 PM writes...

@EngeIGW - it seems to me that the 3D shape of the beast is rather remarkably limited considering its size: out of the 3 rotatable bonds that matter, two of them are co-linear and the third is practically kept parallel to them by the rigid fused triple ring system. I would venture a guess that this shape-change limitation is one of the reasons while it can be successful despite the bulky size.

Permalink to Comment

15. Mark on September 23, 2010 1:43 PM writes...

My question is, what color is it?

Mark

Permalink to Comment

16. anchor on September 23, 2010 1:54 PM writes...

#5 brick dust

on the plus side here is hoping that at the end of the day it is still an amide and that some amidase will hydrolyze (among other metabolism) to release an amine for possible conjugation and eventual elimination.

Permalink to Comment

17. BFS on September 23, 2010 2:54 PM writes...

"Posted by Derek

And I now present today's winner of the Ugliest Molecule To Actually Show In Vivo Efficacy."

To that I say caveat mTOR.

Permalink to Comment

18. andreadelsarto on September 23, 2010 6:41 PM writes...

Needs more cowbell.

Permalink to Comment

19. Jose on September 23, 2010 8:28 PM writes...

Reminds me of Praziquantel.

Permalink to Comment

20. AlchemistOrganique on September 23, 2010 9:16 PM writes...

Can anyone propose a better explanation for this compound's selectivity? It also looks like a wicked DNA/RNA intercalator.

Permalink to Comment

21. barry on September 24, 2010 12:21 AM writes...

rapamycin has been shown to have anti-cancer activity in the clinic. Because it inhibits mTOR only indirectly (and therefore blocks signalling down only one leg of the cascade) interest persists in a direct (presumably ATP-competitive) inhibitor of all mTOR activity.

Permalink to Comment

22. kristall36 on September 24, 2010 1:48 AM writes...

Derek,

how do you think about Merck's mPGES-1 inhibitor?

Permalink to Comment

23. DrSnowboard on September 24, 2010 5:50 AM writes...

Black Swans of Chemistry?
I give you HCV inhibitor BMS-790052, mwt 738ish, clogP>4.5, currently going great guns in Phase2+.

Permalink to Comment

24. noname on September 24, 2010 7:21 AM writes...

#23:

HCV compounds are poor comparisons, because unlike most oral drugs, they need never leave the liver. That's why the BI, VX, and BMS compounds can be so big. Doesn't help that the target is a SOB and can only be hit be big peptidomimetics.

Permalink to Comment

25. canchem on September 24, 2010 8:08 AM writes...

BFS - funniest thing I've read in a loooong time.

Permalink to Comment

26. DrSnowboard on September 24, 2010 9:45 AM writes...

Maybe, but isn't the numbers game centred on oral absorption? I don't remember my liver being on the inside of my GI tract, but I am only a chemist. BMS cpd isn't an NS3/4 protease inhibitor either.

Permalink to Comment

27. myma on September 24, 2010 10:46 AM writes...

It looks like a hERG inhibitor to me.
and maybe a conductive paint additive too.

Permalink to Comment

28. Greg on September 24, 2010 12:43 PM writes...

Ariad's ridaforolimus is an mTOR and we will see shortly just how much that molecule has in terms of efficacy in the clinics.......

Permalink to Comment

29. barry on September 24, 2010 1:49 PM writes...

re#28
ridaforolimus inhibits mTOR only indirectly, and therefore blocks only one of two legs of signalling, just like rapamycin. We still want to know whether a direct inhibitor blocking both legs of signalling would be better for oncology.

Permalink to Comment

30. HTSguy on September 25, 2010 8:42 PM writes...

Small wonder about BMS-790052 working in vivo despite it's size, etc. It's 50pM in cellular assays!

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern